A2AR Expression and Immunosuppressive Environment Independent of

A2AR CD39 CD73 PDL-1 pseudomyxoma peritonei

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
20 Jul 2023
Historique:
received: 25 05 2023
revised: 07 07 2023
accepted: 18 07 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

In pseudomyxoma peritonei (PMP),

Identifiants

pubmed: 37509688
pii: biomedicines11072049
doi: 10.3390/biomedicines11072049
pmc: PMC10377259
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Italian Association for Cancer Research
ID : AIRC IG 2016 Id.19206

Références

Cancer Discov. 2016 Mar;6(3):256-69
pubmed: 26715642
Cancer Cell. 2005 May;7(5):411-23
pubmed: 15894262
Sci Signal. 2016 May 31;9(430):ra56
pubmed: 27245613
PLoS One. 2013 Sep 06;8(9):e73616
pubmed: 24040001
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Nat Rev Immunol. 2016 Mar;16(3):177-92
pubmed: 26922909
PLoS One. 2017 Jun 22;12(6):e0179510
pubmed: 28640835
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
pubmed: 16916931
Int J Mol Sci. 2018 Dec 02;19(12):
pubmed: 30513816
J Cancer Res Clin Oncol. 2018 Jul;144(7):1253-1263
pubmed: 29725763
Immunotherapy. 2017 Mar;9(4):347-360
pubmed: 28303764
J Pathol Clin Res. 2019 Oct;5(4):217-226
pubmed: 31136102
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35135866
Eur J Surg Oncol. 2022 Jul;48(7):1590-1597
pubmed: 35090796
Clin Cancer Res. 2018 Jun 15;24(12):2859-2872
pubmed: 29602801
Surg Oncol Clin N Am. 2003 Jul;12(3):585-603
pubmed: 14567019
Ann Oncol. 2016 Nov;27(11):2097-2103
pubmed: 27502722
Lancet Oncol. 2006 Jan;7(1):69-76
pubmed: 16389186
Oncotarget. 2016 Aug 23;7(34):55828-55839
pubmed: 27331871
Front Immunol. 2019 Jul 30;10:1790
pubmed: 31417563
Nat Rev Cancer. 2017 Dec;17(12):709-724
pubmed: 29059149
Nat Rev Cancer. 2013 Dec;13(12):842-57
pubmed: 24226193
J Transl Med. 2016 May 06;14(1):125
pubmed: 27154293
Cancer. 1995 Feb 1;75(3):757-68
pubmed: 7828125
J Mol Diagn. 2018 Sep;20(5):635-642
pubmed: 29936255
Am J Clin Oncol. 2018 Aug;41(8):777-783
pubmed: 28263231
Histopathology. 2017 Dec;71(6):847-858
pubmed: 28746986
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Cell Signal. 2014 May;26(5):1060-7
pubmed: 24486403
Adv Exp Med Biol. 2019;1136:113-121
pubmed: 31201720
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
Oncotarget. 2017 Nov 6;8(63):106888-106900
pubmed: 29290997
Medicine (Baltimore). 2020 Jul 31;99(31):e20963
pubmed: 32756083
Curr Opin Pharmacol. 2016 Aug;29:90-6
pubmed: 27429212

Auteurs

Shigeki Kusamura (S)

Peritoneal Surface Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Adele Busico (A)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Elena Conca (E)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Iolanda Capone (I)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Luca Agnelli (L)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Daniele Lorenzini (D)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Silvia Brich (S)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Marta Angelini (M)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Chiara Costanza Volpi (CC)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Desirè Viola Trupia (DV)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Vincenzo Lagano (V)

1st Pathology Division, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Tommaso Torelli (T)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Annunziata Gloghini (A)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Dario Baratti (D)

Peritoneal Surface Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Marcello Guaglio (M)

Peritoneal Surface Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Massimo Milione (M)

1st Pathology Division, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Marcello Deraco (M)

Peritoneal Surface Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Federica Perrone (F)

Laboratory of Diagnostic and Molecular Research, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Classifications MeSH